论文部分内容阅读
目的:探讨热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿临床疗效及安全性。方法:选择65例多重耐药菌呼吸道感染患儿进行随机分组对照研究,对照组32例患儿予头孢哌酮舒巴坦静点治疗,治疗组33例患儿在此基础上予热毒宁注射液辅助治疗,3 d为1个疗程,两组患儿均治疗1个疗程。通过比较治疗前后两组患儿临床症状变化以及治疗后的总有效率和TESS评分来探究热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿临床疗效及安全性。结果:治疗前,两组患儿发热症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的发热症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗前,两组患儿流涕症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的流涕症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗前,两组患儿咳嗽症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的咳嗽症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗3 d后,对照组治愈11例(34.38%),好转13例(40.63%),无效8例(25.00%),总有效率为75.00%;治疗组治愈18(56.25%)例好转14(42.42%)无效1(3.03%),总有效率为90.91%。治疗组的治疗有效率比对照组较高(P<0.05)。在治疗1 d时,对照组TESS评分为1.23±0.17,治疗组TESS评分为1.25±0.15,两组之间无明显差异(P>0.05);治疗3 d时对照组TESS评分为1.32±0.18,治疗组TESS评分为1.34±0.19,两组TESS评分无明显差异(P>0.05)。结论:热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿的治疗有良好的临床疗效而且及安全性较好。
OBJECTIVE: To investigate the clinical efficacy and safety of combination thermodin and cefoperazone sulbactam sodium in children with multi-drug resistant respiratory tract infection. Methods: A total of 65 children with multiple drug-resistant bacterial respiratory tract infections were randomly divided into control group, 32 patients in the control group were treated with cefoperazone sulbactam intravenously, and 33 children in the treatment group were treated with heat-toxin Injection adjuvant therapy, 3 d for a course of treatment, two groups of children were treated with a course of treatment. The clinical efficacy and safety of Revitonine plus cefoperazone and sulbactam sodium in children with multi-drug resistant respiratory tract infection were explored by comparing the changes of clinical symptoms and the total effective rate and TESS score after treatment. Results: Before treatment, there was no significant difference in febrile symptom scores between the two groups (P> 0.05). After treatment, the fever symptom scores of both groups were decreased (P <0.05), and the score of the treatment group was higher than that of the control group Low (P <0.05). Before treatment, there was no significant difference in runny nose symptom scores between the two groups (P> 0.05). After treatment, the scores of runny nose symptoms in both groups were decreased (P <0.05), and the score of treatment group was higher than that of control group Low (P <0.05). Before treatment, there was no significant difference in cough symptom scores between the two groups (P> 0.05). After treatment, the cough symptom scores of both groups were decreased (P <0.05), and the score of the treatment group was lower than that of the control group P <0.05). After 3 days of treatment, the control group was cured in 11 cases (34.38%), improved in 13 cases (40.63%), ineffective in 8 cases (25.00%), the total effective rate was 75.00% 42.42%) invalid 1 (3.03%), the total effective rate was 90.91%. The therapeutic efficiency of the treatment group was higher than that of the control group (P <0.05). The TESS score was 1.23 ± 0.17 in the control group and 1.25 ± 0.15 in the treatment group at 1 d after treatment. There was no significant difference between the two groups (P> 0.05). The TESS score of the control group was 1.32 ± 0.18 at 3 d after treatment, TESS score of the treatment group was 1.34 ± 0.19, there was no significant difference between the two groups (P> 0.05). CONCLUSION: The combination of Rendoxin and cefoperazone sulbactam sodium has good clinical efficacy and safety for children with multi-drug resistant respiratory tract infection.